Innovation will continue to drive the pharma and biotech sectors in 2015 as forecasts point to another prosperous year according to EP Vantage’s report, Pharma & Biotech 2015 Preview, based on EvaluatePharma data.

Key highlights include: 

• A dozen products due to be launched next year are forecast to achieve blockbuster sales by 2020

• Drugs treating high cholesterol and heart failure will dominate the field with a combined 2020 sales forecast of $8 billion

• Sovaldi and its combination product Harvoni will take the number one worldwide seller spot with forecasted sales of $15.3 billion in 2015

• Patent expiries will have minimal impact on the top line as 2015 sales will grow close to four times that of patent losses

• Financing climate appears friendly and deals will continue at a steady pace but M&A activity unlikely to match the frenzy of 2014.

To download this report, please confirm your details on the form opposite.